Chemistry: analytical and immunological testing – Thyroid hormone tests
Reexamination Certificate
1998-02-26
2002-06-25
Park, Hankyel T. (Department: 1648)
Chemistry: analytical and immunological testing
Thyroid hormone tests
C436S501000, C436S516000, C435S003000, C435S004000
Reexamination Certificate
active
06410339
ABSTRACT:
BACKGROUND
The metabolic syndrome is characterized by an increased amount of adipose tissue inside the abdominal cavity (popularly called belly fatness), insulin resistance with increased risk of developing senile diabetes, i.e. diabetes type II (=NIDDM, non-insulin dependent diabetes mellitus), high levels of blood fats and high blood pressure. Parallel to this is an increased risk of coronary, apoplexy, sudden death and other arteriosclerotic conditions.
A hypothetical explanation to the metabolic syndrome could be an overproduction of cortisol, a stress hormone which causes an accumulation of fat inside the abdominal cavity, and insulin resistance. Theoretically this could, through secondary metabolic effects, explain the other disorders related to the metabolic syndrome.
In Metabolism, vol. 41, No 8, 1992, pages 882-886, it is shown that belly fat women have higher secretion of cortisol than “evenly fat” women. The same work describes the effects of acute mental stress on the production of cortisol. It was shown that belly fat women, at a given stress signal, produced more cortisol than ‘evenly fat’ women. This suggested, but did not prove, that there may be a relationship between stress and belly obesity. A dexamethasone inhibitor test was carried out with 1 mg dexamethasone and subsequent measurement of cortisol content in serum. No difference in inhibitory effect on the production of cortisol could be found between the groups of belly fat women and evenly fat women and standard values.
Cortisol analogues, e.g. dexamethasone, have for many years been used to track so called endogenous (often hereditary) depressions in humans. The mechanism behind the test is however so far unknown.
OBJECT OF THE INVENTION AND MOST IMPORTANT CHARACTERISTICS
The object of the present invention is to find a diagnostic test by which individuals, running the risk of being affected by one or more of the symptoms and/or conditions characteristic to the above described metabolic syndrome, can be identified at an early stage. In the present invention this is accomplished by a diagnostic system, which as an active substance has cortisol agonists of a dose in an interval in which a difference in the inhibitory effect of the autonomous cortisol production between individuals with the metabolic syndrome or one or more of the related risk/conditions and normal values are obtained. Preferably the cortisol agonist is a synthetic cortisol analogues with a glucocorticoidal and/or mineral corticoidal effect, e.g. dexamethasone. The invention also concerns a diagnostic system for the purpose of diagnosing the metabolic syndrome, comprising a cortisol agonist of a dosage described above, and an agent for measuring the content of cortisol in saliva or serum.
REFERENCES:
Atkinson, et al. : A weight-related intravenous dexamethosone . . . : Acta Indocrin.: 120, 6: pp. 753-759, 1989.*
Croughs, et al. : Comparison of oral and intravenous dexamethosome . . . : Acta Indocrin.: 72: pp. 51-62, 1973.*
Montwill, et al. : The overweight dexamethasone test is the procedure . . . : Steroids: 59: pp. 296-298, May 1994.*
Bennington, et al: Saunders dictionary & encyclopedia of laboratory medicing and technology: p. 398, Jan. 1987.*
Hormone and metabolic research, vol. 22, 1990 pp. 553-554 Hagg, et al; Salivory Control during an . . .
Neuropsychobiology, vol. 22, 1989: pp. 26-32 Maes et al; Results of the 8 a.m. dexamethasone . . .
DN Brindley, Role of glucocorticoids and fatty acids in the impairment of lipid metabolism observed in the metabolic syndrome, International Journal of Obesity (1995) 19, Suppl. 1 S69-S75.
Niklas Darin, Telko Amemiya, Bjorn Anderson, Sverker Jern and Per Bjorntorp, Cortisol Secretion in Relationship to Body Fat Distribution in Obese Premenopausal Women, Metabolism, vol. 41, No. 8 (Aug.) 1992 pp. 882-888.
Rett-K, Wicklmayr-M, Standl-E, The metabolic syndrome, Pathopysiologic causes, diagnosis, therapy, Wien-Klin-Wochenschr, 1994; 106(24);750-7 published in Austria.
Gries-FA, Hubinger-A, Lipid metabolism and insulin resistance—clinical aspects and pathobiochemistry, Wein-Klin-Wochenschr 1994;106(24):763-7, published in Austria.
Steinmetz-A, Schafer-JR, Secondary disroders of lipid metabolism, metabolic syndrome and familial combined hyperlimidemia, Wein-Med-Wochenschr 1994; 144(12-13):299-307, published in Austria.
Muller-Wienand-D, Drone-W, Disorders of lipid metabolism in insulin resistance, Herz. Feb. 1995 20(1):33-46, published in Austria.
Moiseev-VS, Ivleva-AIA, Kobalava-ZHD, Hypertension, diabetes mellitus, atherosclerosis: clinical manifestations of metabolic syndrome X. Prospects of pharmacological treatment, Vestn-Ross-Akad-=Med-Nauk 1995(5):15-8, printed in Austria.
Brown S. S.
Cortenda AB
Park Hankyel T.
Ruben Bradley N.
LandOfFree
Preparation for diagnosis of the metabolic syndrome and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Preparation for diagnosis of the metabolic syndrome and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Preparation for diagnosis of the metabolic syndrome and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2935991